Skip to main content
EMVISION MEDICAL DEVICES LTD logo

EMVISION MEDICAL DEVICES LTD — Investor Relations & Filings

Ticker · EMV ISIN · AU0000028375 ASX Manufacturing
Open in API
Filings indexed 303 across all filing types
Latest filing 2026-05-24 Capital/Financing Update
Country AU Australia
Listing ASX EMV

About EMVISION MEDICAL DEVICES LTD

https://emvision.com.au/

EMVision Medical Devices Ltd is a medical technology company focused on the development and commercialization of portable medical imaging devices. The company specializes in electromagnetic microwave imaging technology designed for the rapid diagnosis and monitoring of stroke and traumatic brain injury. Its primary product is a portable brain scanner intended for use at the point of care, including intensive care units, emergency departments, and ambulances. By utilizing non-ionizing radiation, the technology provides a safe, cost-effective, and mobile alternative to traditional neuroimaging modalities like CT and MRI. The device aims to facilitate earlier clinical intervention by enabling bedside assessment, potentially improving patient outcomes through faster detection of ischemic and hemorrhagic strokes.

Recent filings

Filing Released Lang Actions
EMVision to Receive $1.17M IGP Grant Instalment 2 pages 197.4KB
Capital/Financing Update Classification · 84% confidence The document is an ASX regulatory release announcing that EMVision Medical Devices has reached a milestone to receive the next installment of a $5 million non-dilutive Industry Growth Program (IGP) grant. It provides details of the grant, past receipts, and future funding available. There are no financial statements, earnings metrics, or meeting materials—it is purely an update on grant funding (a financing activity). Therefore it fits the Capital/Financing Update category (CAP).
2026-05-24 English
Application for quotation of securities - EMV 7 pages 21.7KB
Share Issue/Capital Change Classification · 86% confidence The document is an ASX Appendix 2A form notifying the quotation of new securities issued upon exercise of options/performance rights. It details the number and type of securities, issue dates, and post-quotation capital structure. This is a capital change announcement (new share issue) rather than an annual or interim report, dividend notice, or regulatory certification. Therefore, it fits the “Share Issue/Capital Change” category.
2026-05-11 English
Cleansing Notice 1
Share Issue/Capital Change Classification · 85% confidence The document is an ASX release titled 'CLEANSING NOTICE' confirming the issuance of 16,957 fully paid ordinary shares relating to the exercise of performance rights under the Company’s Employee Incentive Plan. It announces a new share issue (Appendix 2A) under section 708A of the Corporations Act, clearly fitting the definition of a share issue/capital change. There is no indication of a share buyback or other category. Therefore, the correct classification is Share Issue/Capital Change (SHA).
2026-05-11 English
emu Pivotal Trial Expansion Adds Acute Ischaemia Detection 6 pages 382.0KB
Regulatory Filings Classification · 85% confidence The document is an ASX release providing a clinical program update on the emu™ Pivotal (Validation) Trial, including trial expansion, recruitment progress, regulatory pathway updates, and funding acknowledgements. It is an operational / corporate announcement rather than a financial report (10-K, IR), earnings release (ER), investor presentation (IP), or capital/financing notice (CAP). It does not contain substantive financial statements or executive certifications. It is a general regulatory announcement on ASX, fitting the fallback category for miscellaneous regulatory filings (RNS).
2026-05-10 English
Change of Director's Interest Notice 2 pages 283.5KB
Director's Dealing Classification · 95% confidence The document is an ASX Appendix 3Y “Change of Director’s Interest Notice,” disclosing a director’s acquisition of shares and options under Listing Rule 3.19A.2. This is exactly a report of personal share transactions by a company director (insider dealing). Therefore it falls under the “Director’s Dealing” category with code DIRS.
2026-04-23 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 373.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'APPENDIX 4C – 31 MARCH 2026 QUARTERLY ACTIVITIES & CASHFLOW REPORT' and provides detailed operational and financial updates for the quarter ended 31 March 2026. It includes substantive financial data such as cash reserves, R&D tax refunds, grant funding, operating cash inflows, and expenditure breakdowns. The content covers clinical trial progress, regulatory activities, and financial performance for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements or substantive financial data and analysis. The document is lengthy (15,000 characters) and not merely an announcement or certification, so it is not an RPA or RNS. Therefore, the correct classification is IR with high confidence.
2026-04-12 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.